Indication
Neuroendocrine Prostate Cancer
4 clinical trials
4 products
Product
PT217Clinical trial
A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3.Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2025-08-23
Product
TarlatamabClinical trial
An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate CancerStatus: Recruiting, Estimated PCD: 2023-05-01
Product
ORIC-944Clinical trial
An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid CancersStatus: Withdrawn, Estimated PCD: 2025-04-30
Product
Regorafenib